Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966347 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL12410772 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL23612391 | 0.75 | ALDH1A1 (0.46) | LMNAALDH1A1KDM4ENPC1TSHR | |
| SCHEMBL21681867 | 0.74 | CDK4 (0.40) | SMN1; SMN2LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL23244457 | 0.74 | PLK1 (0.43) | SMN1; SMN2LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL16339760 | 0.74 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4ENPC1TSHR | |
| SCHEMBL2874305 | 0.72 | HDAC3 (0.57) | KDM4ECYP2C19TSHR | |
| SCHEMBL12410773 | 0.72 | NPSR1 (0.45) | SMN1; SMN2LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL669675 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL10597853 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAMAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-7446110-B2 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| US-5550240-A | Piperazinyl-bis(alkylamino)pyrimidine derivatives and process for preparing same | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1996-08-27 | — | — | US | disclosed |
| EP-0644882-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025539-A1 | NOVEL PIPERZINYL-BIS(ALKYLAMINO)PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | SMN1; SMN2 96/4885LMNA 3313/4885MAPT 246/4885 |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | SMN1; SMN2 4433/4885LMNA 4824/4885MAPT 2286/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885LMNA 1395/4885MAPT 3828/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | SMN1; SMN2 2231/4885LMNA 3212/4885MAPT 2065/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | SMN1; SMN2 92/4885LMNA 3160/4885MAPT 423/4885 |
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BRCA1, ABAT, HDAC1 | SMN1; SMN2 86/4885LMNA 880/4885MAPT 42/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SMN1; SMN2 285/4885LMNA 716/4885MAPT 4649/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | SMN1; SMN2 1745/4885LMNA 2668/4885MAPT 2768/4885 |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | AR, CYP17A1, SHBG | SMN1; SMN2 1935/4885LMNA 2166/4885MAPT 3061/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | SMN1; SMN2 96/4885LMNA 3313/4885MAPT 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.